Development of new pharmacological approaches in Parkinson's disease.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D003548:Cysteinyldopa / Q000378:metabolism; D003692:Delayed-Action Preparations; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D011725:Pyridines / Q000633:toxicity; D011954:Receptors, Dopamine / Q000187:drug effects; D013329:Structure-Activity Relationship
D000978:Antiparkinson Agents; D003692:Delayed-Action Preparations; D011725:Pyridines; D011954:Receptors, Dopamine; D003548:Cysteinyldopa; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine